COMPANY
Bambusa Therapeutics
Timeline
- Trial start Phase 1/Phase 2: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants W source ↗
- Trial start Phase 1/Phase 2: A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma source ↗
- Trial start Phase 1: A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD) source ↗
- Trial start Phase 1: A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) source ↗
- Trial start Phase 1: A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) source ↗
- Trial start Phase 1: A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) source ↗
Upcoming milestones
- Dec 31, 2026 (ESTIMATED) · Phase 1 · A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD) · NCT07288554
- Jan 31, 2027 (ESTIMATED) · Phase 1 · A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) · NCT06944925
- Feb 28, 2027 (ESTIMATED) · Phase 1 · A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) · NCT06808477
- Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma · NCT07436949
- Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spont · NCT07717905
- Dec 31, 2027 (ESTIMATED) · Phase 1 · A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) · NCT07239947
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06808477 | A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) | Phase 1 | Recruiting | Feb 27, 2025 | Feb 28, 2027 (estimated) |
| NCT07436949 | A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma | Phase 1/Phase 2 | Recruiting | Mar 2, 2026 | Dec 31, 2027 (estimated) |
| NCT07288554 | A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Recruiting | Sep 5, 2025 | Dec 31, 2026 (estimated) |
| NCT07717905 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) | Phase 1/Phase 2 | Recruiting | Jun 29, 2026 | Dec 31, 2027 (estimated) |
| NCT07239947 | A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) | Phase 1 | Recruiting | Aug 9, 2025 | Dec 31, 2027 (estimated) |
| NCT06944925 | A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) | Phase 1 | Recruiting | May 8, 2025 | Jan 31, 2027 (estimated) |